Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1998-06-12
2000-10-17
Priebe, Scott D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4353201, 435325, 435455, 536 231, 536 245, 424 9321, A61K 4800, C12P 1934
Patent
active
061332453
ABSTRACT:
A gene is regulated by introducing into a cell an inducible, tissue-specific antisense DNA construct. The antisense DNA construct comprises any inducible, tissue-specific gene, into which a DNA sequence antisense to any DNA sequence of the gene targeted for regulation has been inserted. The inducible, tissue-specific antisense DNA construct transcribes a hybrid messenger RNA containing an RNA sequence antisense to a sequence of the messenger RNA of the gene targeted for regulation. The hybrid messenger RNA also contains the RNA sequence of the inducible, tissue-specific gene. Some examples of suitable inducible genes include those selected from the group consisting of mammalian cytosolic phosphoenolpyruvate carboxykinase (PEPCK) (GTP, EC 4.1.1.32), mammalian atrial natriuretic factor (ANF), and mammalian alpha myosin heavy chain (.alpha.-MHC). In a preferred embodiment, the inducible, tissue-specific gene is the rat PEPCK gene.
REFERENCES:
patent: 4736866 (1988-04-01), Leder et al.
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 5107065 (1992-04-01), Shewmaker et al.
patent: 5175383 (1992-12-01), Leder et al.
patent: 5175384 (1992-12-01), Krimpenfort et al.
patent: 5175385 (1992-12-01), Wagner et al.
patent: 5254800 (1993-10-01), Bird et al.
patent: 5585479 (1996-12-01), Hoke et al.
Plenat (Molecular Medicine Today, vol. 1, 3, 1996, pp. 250-257).
Mullins et al. (J. Clin. Invest., vol. 98, 11, 1996, pp. S37-S40).
Branch (TIBS 23, Feb. 1998, pp. 45-50).
Crowley et al., "Phenocopy of Discoidin I-Minus Mutants by Antisense Transformation in Dictyostelium" Cell (1985) 43:633-641.
Rosenberg et al., "Production of Phenocopies by Kruppel Antisense RNA Injection into Drosophila Embryos" Nature (1985) 313:703-706.
Melton, "Injection Anti-Sense RNAs Specifically Block Messenger RNA Translation in vivo", Proc. Natl. Acad. Sci. USA. (1985) 82:144-148.
Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogenous Genes by Anti-Sense RNA" Science 229:345-352; 1985.
Kim and Wold, "Stable Reduction of Thymidine Kinase Activity in Cells Expressing High Levels of Anti-Sense RNA" Cell (1985) 42:129-138.
Izant and Weintraub, "Inhibition of Thymidine Kinase Gene Expression by Anti-Sense RNA: A Molecular Approach to Genetic Analysis" Cell (1984) 36:1007-1015.
Pestka et al., "Anti-mRNA: Specific Inhibition of Translation of Single mRNA Molecules" Proc. Natl. Acad. Sci. U.S.A. (1984) 81:7525-7528.
Mizuno et. al., "A Unique Mechanism Regulating Gene Expression: Translational Inhibition by a Complementary RNA Transcript (micRNA)" Proc. Natl. Acad. Sci. U.S.A. (1984) 81:1966-1970.
Coleman et al., "The Use of RNAs Complementary to Specific mRNAs to Regulate the Expression of Individual Bacterial Genes" Cell (1984) 37:429-436.
Weintraub et al., "Anti-sense RNA as a Molecular Tool for Genetic Analysis" Trends in Genetics (1985) 1:22-25.
McGarry and Lindquist, "Inhibition of Heat Shock Protein Synthesis by Heat-Inducible Antisense RNA" Proc. Natl. Acad. Sci. U.S.A. (1986) 83:399-403.
Watkins et al., "Regulation of the Differentiation of Teratocarcinoma Cells into Primitive Endodern by G.alpha..sub.i2 " Science (1992) 258:1373-1375.
San, H. et al., "Safety and Short Term Toxicity of a Novel and Cationic Formulation for Human Gene Therapy" Human Gene Therapy (1993) 781-788.
Christofferson, R. et al., "Ribozymes as Human Therapeutic Agents" Journal of Medicinal Chemistry (1994) 1012-2037.
Stull, R. et al., "Antigene, Ribozyme, and Aptomer Nucleic Acid Drugs: Progress and Prospects" Pharmaceuticals Research (1995).
Moxham et al., "Gi alpha 2 Mediates the Inhibitory Regulation of Adenylylcyclase in vivo: Analysis in Transgenic Mice with Gi alpha 2 Suppressed by Inducible Antisense RNA" Developmental Genetics (1993) 14.
Mulligan, "The Basic Science of Gene Therapy" Science (1993) 260; 926-932.
James, "Towards Gene Inhibition Therapy: A Review of Progress and Prospects in the Field of Antiviral Antisense Nucleic Acids and Ribozymes" Antiviral Chemistry and Chemotherapy (1991) 2(4): 191-214.
Uhlmann et al., "Antisense Oligonucleotides: A New Therapeutic Principle" Chemical Reviews (1990) 90(4);543-584.
Weiss, "Upping the Antisense Ante, Scientist Bet on Profits from Reverse Genetics" Science News (1991) 139:108-109.
Gewirtz et al., "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on its Promise" Proc. Natl. Acad. Sci. (1996) 93:3161-3163.
Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy (1995) 1-41; and.
Caskey, "Antisense and Differentiation" Annals of the New York Academy of Sciences (1992) 660:154-158.
Malbon Craig C.
Moxham Christopher M.
Nguyen Dave Trong
Priebe Scott D.
The Research Foundation of State University of New York
LandOfFree
Antisense DNA constructs for expression of hybrid mRNAs driven b does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense DNA constructs for expression of hybrid mRNAs driven b, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense DNA constructs for expression of hybrid mRNAs driven b will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-468979